Aurobindo Enters Fray For COVID-19 Vaccine
Generic to Teva’s Qvar Filed?
Building on assets acquired from Profectus BioSciences, Aurobindo Pharma has thrown its hat in the ring for a COVID-19 vaccine. Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, the company hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges.
You may also be interested in...
Aurobindo expects revenues from injectables to increase to $650-700m over the next three years as its Vizag plant gets commissioned in a year’s time. Apart from seeking organic growth, the company is keeping an eye out for acquisitions in emerging markets though big-ticket ones are ruled out.
Pfizer is unlikely to tie up with Indian companies soon for manufacture of its COVID-19 vaccine as it has built capacity for the first phase. However, as discussions to supply to the COVAX facility and developing countries progress, it could evaluate such opportunities later.
Strides files for a biosimilar to Eli Lilly’s Forteo (teriparatide) in the EU, marking the beginning of its journey in the biosimilars segment. Meanwhile, it hopes to enter a manufacturing tie-up with COVID-19 vaccine players in H2 while also planning a launch of favipiravir in markets outside India.